JP2023521030A - イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法 - Google Patents

イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法 Download PDF

Info

Publication number
JP2023521030A
JP2023521030A JP2022560218A JP2022560218A JP2023521030A JP 2023521030 A JP2023521030 A JP 2023521030A JP 2022560218 A JP2022560218 A JP 2022560218A JP 2022560218 A JP2022560218 A JP 2022560218A JP 2023521030 A JP2023521030 A JP 2023521030A
Authority
JP
Japan
Prior art keywords
cancer
ibudilast
day
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560218A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021207054A5 (https=
JP2023521030A5 (https=
Inventor
裕一 岩城
和子 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of JP2023521030A publication Critical patent/JP2023521030A/ja
Publication of JPWO2021207054A5 publication Critical patent/JPWO2021207054A5/ja
Publication of JP2023521030A5 publication Critical patent/JP2023521030A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022560218A 2020-04-06 2021-04-05 イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法 Pending JP2023521030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005792P 2020-04-06 2020-04-06
US63/005,792 2020-04-06
PCT/US2021/025732 WO2021207054A1 (en) 2020-04-06 2021-04-05 Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast

Publications (3)

Publication Number Publication Date
JP2023521030A true JP2023521030A (ja) 2023-05-23
JPWO2021207054A5 JPWO2021207054A5 (https=) 2024-04-15
JP2023521030A5 JP2023521030A5 (https=) 2024-04-15

Family

ID=75674991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560218A Pending JP2023521030A (ja) 2020-04-06 2021-04-05 イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法

Country Status (6)

Country Link
US (2) US12213966B2 (https=)
EP (1) EP4132521A1 (https=)
JP (1) JP2023521030A (https=)
CN (1) CN115335049A (https=)
CA (1) CA3174413A1 (https=)
WO (1) WO2021207054A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
WO2023150093A1 (en) * 2022-02-01 2023-08-10 Medicinova, Inc. Ibudilast for use in the treatment of post-covid conditions
JP2025523822A (ja) * 2022-07-13 2025-07-25 メディシノバ・インコーポレイテッド イブジラストの注射用製剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221629A1 (en) * 2006-05-31 2009-09-03 Avigen, Inc. Method for antagonizing MIF activity
US20110028510A1 (en) * 2009-02-18 2011-02-03 Combinatorx (Singapore) Pte. Ltd. Compositions, Methods, and Kits for Treating Influenza Viral Infections
JP2020504721A (ja) * 2016-12-22 2020-02-13 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラストを使用した多形膠芽腫の治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1106178T3 (da) 1998-08-10 2005-02-28 Kyorin Seiyaku Kk Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
SG148198A1 (en) 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
CA2970273C (en) 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
US20190247369A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221629A1 (en) * 2006-05-31 2009-09-03 Avigen, Inc. Method for antagonizing MIF activity
US20110028510A1 (en) * 2009-02-18 2011-02-03 Combinatorx (Singapore) Pte. Ltd. Compositions, Methods, and Kits for Treating Influenza Viral Infections
JP2020504721A (ja) * 2016-12-22 2020-02-13 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラストを使用した多形膠芽腫の治療方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 55, JPN6025012170, 2014, pages 1 - 6, ISSN: 0005563308 *
MED. SCI. MONIT., vol. 26, JPN6025012168, 31 March 2020 (2020-03-31), pages 922281 - 1, ISSN: 0005697120 *
ZACKS SMALL-CAP RESEARCH, JPN6025012169, 12 March 2020 (2020-03-12), ISSN: 0005697121 *

Also Published As

Publication number Publication date
US12213966B2 (en) 2025-02-04
CA3174413A1 (en) 2021-10-14
EP4132521A1 (en) 2023-02-15
CN115335049A (zh) 2022-11-11
US20250221969A1 (en) 2025-07-10
WO2021207054A1 (en) 2021-10-14
US20210308109A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP2023521030A (ja) イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法
CN101848712B (zh) 用异丁地特治疗渐进性神经变性疾病
US20260060964A1 (en) Methods and compositions for treating sepsis
US9750739B2 (en) Orvepitant for chronic cough therapy
KR20260004440A (ko) 종양 괴사 인자 알파의 소분자 저해제를 사용한 건선 치료
US20210177812A1 (en) Methods of suppressing myeloid-derived suppressor cells in patients
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
US12005049B2 (en) Methods of preventing cancer metastasis
Lee et al. Levofloxacin pharmacokinetics in adult cystic fibrosis
JP2022505184A (ja) イブジラストを用いて眼疾患／障害または損傷を治療する方法
US12042485B2 (en) Methods of minimizing cancer metastasis
EP3131545A2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
Jiang et al. Delivery system for targeted drug therapy in chronic diseases
KR102216319B1 (ko) 히드록시유레아를 포함하는 전신성 염증 억제용 약학 조성물 및 이의 제형
Tudományegyetem SZTE TIK| Szegedi Tudományegyetem| Particle engineering for formulation of dry powder inhalation systems applicable in lung diseases
JP2025523822A (ja) イブジラストの注射用製剤
HK40069821B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
JPS5888311A (ja) 呼吸器疾患治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250930